Risk factors of bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention: an analysis from the MANJUSRI study - Report - MDSpire
Advertisement
Risk factors of bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention: an analysis from the MANJUSRI study
Clinical Report: Identifying Bleeding Risk Factors in Atrial Fibrillation Patients
Overview
The MANJUSRI trial highlights significant bleeding risk factors in atrial fibrillation patients undergoing PCI. Key findings indicate that alcohol consumption and age are associated with increased bleeding risk, while lower body mass index correlates negatively with bleeding risk in certain therapy groups.
Background
Atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) face a complex balance between preventing thrombotic events and managing bleeding risks associated with antithrombotic therapies. Understanding the risk factors for bleeding is crucial for optimizing treatment strategies and improving patient outcomes. The MANJUSRI trial provides valuable insights into these risk factors, particularly in the context of dual and triple therapy regimens.
Data Highlights
Group
Overall Bleeding Incidence at 6 Months
Dual Therapy (Ticagrelor + Warfarin)
36.49%
Triple Therapy (Clopidogrel + Aspirin + Warfarin)
35.62%
Key Findings
Alcohol consumption is positively correlated with overall bleeding risk (OR = 3.905, P = 0.001).
In the dual therapy group, alcohol consumption increases bleeding risk (OR = 4.643, P = 0.034).
Age is positively associated with overall bleeding risk (OR = 1.059, P = 0.032).
Lower body mass index is negatively associated with overall bleeding risk in the triple therapy group (OR = 0.911, P = 0.048).
The incidence of overall bleeding at 6 months is comparable between dual and triple therapy groups (P > 0.05).
Clinical Implications
Clinicians should consider alcohol consumption and age as significant risk factors when managing anticoagulation therapy in AF patients post-PCI. Additionally, attention to body mass index may help in tailoring treatment strategies to minimize bleeding risks.
Conclusion
The findings from the MANJUSRI trial underscore the importance of individualized anticoagulation management in atrial fibrillation patients undergoing PCI, particularly regarding modifiable risk factors for bleeding.
